Eli Lilly and Company (NYSE:LLY) Stock Price Down 3.8% – What’s Next?

Eli Lilly and Company (NYSE:LLY) dropped 3.8% during mid-day trading on Thursday . The stock traded as low as $1,012.57 and last traded at $1,032.5070. Approximately 4,171,949 shares changed hands during trading, an increase of 38% from the average daily volume of 3,026,697 shares. The stock had previously closed at $1,073.29.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly announced a strategic, high‑profile partnership with Nvidia to build an AI drug‑discovery co‑innovation lab (reported as a $1B initiative). This reinforces long‑term R&D acceleration and secular growth optionality beyond GLP‑1s. Nvidia And Eli Lilly To Build $1 Billion AI-Powered Drug Discovery Lab
• Positive Sentiment: J.P. Morgan coverage and conference commentary highlighted continued GLP‑1 momentum and Q4 sales beats, supporting near‑term revenue visibility from Mounjaro/Zepbound. JPM Day 1: Obesity Front-and-Center, Q4 Sales Beats
• Positive Sentiment: Analysts remain constructive—Jefferies and other houses have reaffirmed Buy ratings and elevated price targets, underscoring continued conviction in Lilly’s incretin franchise and pipeline. Where is Eli Lilly and Company (LLY) Headed According to Analysts?
• Neutral Sentiment: JPM coverage also flagged Lp(a) programs as a longer‑duration cardiovascular growth vector—important for multi‑year upside but not immediate revenue. JPM26: Eli Lilly highlights Lp(a) drugs as cardiovascular growth focus
• Neutral Sentiment: Analyst/market pieces note that Mounjaro and Zepbound demand should support Q4 results despite pricing pressure—this is supportive for earnings but already priced into lofty multiples. How Will Mounjaro and Zepbound Sales Aid LLY’s Upcoming Q4 Results?
• Negative Sentiment: A compounding pharmacy (Strive Specialties) filed an antitrust suit alleging coordinated actions by Lilly and Novo Nordisk around GLP‑1 market dominance; litigation risk raises uncertainty around pricing, distribution and competitive behavior. Lilly, Novo sued over GLP‑1 drug dominance by compounding pharmacy
• Negative Sentiment: The FDA reportedly delayed its decision on Lilly’s oral obesity candidate (orforglipron), a setback that reduces the chance of near‑term incremental market share versus rivals and prompted immediate selling pressure. FDA Delays Decision for Lilly’s Obesity Pill Orforglipron, Other Priority Voucher Awardees: Report
• Negative Sentiment: Market coverage tied the FDA delay to an intraday ~5% move downward and broader headlines explaining why LLY is down today—amplifying short‑term volatility. Eli Lilly Stock (LLY) Falls 5% After FDA Delays Decision on Company’s Weight-Loss Pill

Analysts Set New Price Targets

Several research analysts recently commented on the company. Zacks Research upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 1st. Morgan Stanley lifted their target price on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the stock an “overweight” rating in a report on Monday, November 24th. Wolfe Research boosted their target price on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a research report on Wednesday, December 3rd. Deutsche Bank Aktiengesellschaft increased their price target on Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Finally, HSBC reaffirmed a “hold” rating and set a $1,070.00 price objective on shares of Eli Lilly and Company in a research note on Wednesday, December 10th. Five analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $1,169.00.

Eli Lilly and Company Stock Down 3.8%

The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The company has a 50-day simple moving average of $1,047.15 and a 200 day simple moving average of $867.23. The company has a market cap of $976.11 billion, a P/E ratio of 50.51, a P/E/G ratio of 0.78 and a beta of 0.35.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business’s revenue was up 53.9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of LLY. Sumitomo Mitsui Financial Group Inc. bought a new position in shares of Eli Lilly and Company during the second quarter valued at approximately $27,000. Vermillion & White Wealth Management Group LLC lifted its position in shares of Eli Lilly and Company by 84.2% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after buying an additional 16 shares during the last quarter. Evolution Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company during the second quarter valued at about $29,000. Steph & Co. boosted its holdings in shares of Eli Lilly and Company by 290.0% in the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after buying an additional 29 shares in the last quarter. Finally, Financial Gravity Companies Inc. purchased a new position in shares of Eli Lilly and Company in the 2nd quarter worth approximately $31,000. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.